Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 5/20 | 0.33 |
| ▸ | MAPT | P10636 | 4/20 | 0.31 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | CRHBP | P24387 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.31 |
| ▸ | TTR | P02766 | 1/20 | 0.30 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.30 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.30 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.30 |
| ▸ | AR | P10275 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pyridine SCHEMBL920961 | 0.93 | CRHR1 (0.33) | CRHR1MAPTLMNANPC1RAB9A | |
| Hydrochloric Acid SCHEMBL547963 | 0.87 | — | — | |
| Hydrochloric Acid SCHEMBL1194185 | 0.86 | ALDH1A1 (0.34) | LMNASMN1; SMN2MEN1KMT2AALOX5 | |
| Iodide SCHEMBL3672824 | 0.84 | — | — | |
| Bromide SCHEMBL3667202 | 0.84 | — | — | |
| Hydrochloric Acid SCHEMBL6100055 | 0.83 | CRHR1 (0.31) | CRHR1 | |
| Hydrochloric Acid SCHEMBL14574620 | 0.79 | CRHR1 (0.30) | CRHR1 | |
| SCHEMBL13238426 | 0.76 | MAPT (0.39) | CRHR1MAPTLMNANPC1RAB9A | |
| Hydrochloric Acid SCHEMBL3698487 | 0.75 | ALDH1A1 (0.39) | MAPTRAB9AMEN1KMT2AAR | |
| Hydrochloric Acid SCHEMBL3703679 | 0.75 | AR (0.33) | MAPTARALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7696398-B2 | Stabilization of olefin metathesis product mixtures | Dow GlobalTTechnologies, Inc. (US) | 2010-04-13 | — | — | US | claimed |
| EP-1713790-A2 | METHOD OF PREPARATION OF BENZOFURAN-2-CARBOXYLIC ACID (S)-3-METHYL-1- ((4S, 7R)-7METHYL-3-OXO-1-(PYRIDINE-2-SULFONYL)-AZ EPAN-4-YLCARBAMOYL-BUTYL)-AMIDE | SMITHKLINE BEECHAM CORPORATION (US) | 2006-10-25 | — | — | EP | claimed |
| WO-2005069981-A2 | METHOD OF PREPARATION OF BENZOFURAN-2-CARBOXYLIC ACID {(S)-3-METHYL-1-[(4S, 7R)-7METHYL-3-OXO-1-(PYRIDINE-2-SULFONYL)-AZEPAN-4-YLCARBAMOYL]-BUTYL}-AMIDE | SMITHKLINE BEECHAM CORPORATION (US) | 2005-08-04 | — | — | WO | claimed |
| US-20020015519-A1 | Fiber substrate adhesion and coatings by contact metathesis polymerization | LORD CORPORATION | 2002-02-07 | — | — | US | claimed |
| US-9688693-B2 | NK1 antagonists | OPKO HEALTH, INC. (US) | 2017-06-27 | — | — | US | disclosed |
| US-20140336158-A1 | NK1 ANTAGONISTS | TERSERA THERAPEUTICS LLC | 2014-11-13 | — | — | US | disclosed |
| US-8796299-B2 | NK1 antagonists | OPKO HEALTH, INC. (US) | 2014-08-05 | — | — | US | disclosed |
| US-20130023503-A1 | NK1 ANTAGONISTS | OPKO HEALTH, INC. (US) | 2013-01-24 | — | — | US | disclosed |
| US-8329924-B2 | Compounds and methods for the treatment or prevention of Flavivirus infections | VERTEX PHARMACEUTICALS (CANADA) INCORPORATED (CA) | 2012-12-11 | — | — | US | disclosed |
| US-8273895-B2 | NK1 antagonists | OPKO HEALTH, INC. (US) | 2012-09-25 | — | — | US | disclosed |
| US-20090149444-A1 | Benzylamine analogues | BTG INTERNATIONAL LIMITED (GB) | 2009-06-11 | — | — | US | disclosed |
| US-7504393-B2 | Benzylamine analogues | BTG INTERNATIONAL LIMITED (GB) | 2009-03-17 | — | — | US | disclosed |
| US-20060115448-A1 | Amphiphilic polynorbornene derivatives and methods of using the same | UNIVERSITY OF MASSACHUSETTS | 2006-06-01 | — | — | US | disclosed |
| US-7049320-B2 | Drugs for treating physiological disorder, respiratory disorders, inflammatory disease, skin disorder, and antidepressants, treating bipolar disorder, drug abuse, drug dependence, gastrointestinal disorder, atherosclerosis | SCHERING CORPORATION (US) | 2006-05-23 | — | — | US | disclosed |
| WO-2006040148-A1 | TRICYCLIC INDOLE DERIVATIVES FOR USE IN THE TREATMENT OF ALZHEIMER’S DISEASE | GLAXO GROUP LIMITED (GB) | 2006-04-20 | — | — | WO | disclosed |
| WO-2006040151-A1 | SUBSITUTED HYDROXYETHYLAMINE COMPOUNDS FOR TREATING ALZHEIMER’S DISEASE | GLAXO GROUP LIMITED (GB) | 2006-04-20 | — | — | WO | disclosed |
| WO-2005069981-A2 | METHOD OF PREPARATION OF BENZOFURAN-2-CARBOXYLIC ACID {(S)-3-METHYL-1-[(4S, 7R)-7METHYL-3-OXO-1-(PYRIDINE-2-SULFONYL)-AZEPAN-4-YLCARBAMOYL]-BUTYL}-AMIDE | SMITHKLINE BEECHAM CORPORATION (US) | 2005-08-04 | — | — | WO | disclosed |
| US-20050009804-A1 | Compounds and methods for the treatment or prevention of Flavivirus infections | VERTEX PHARMACEUTICALS (CANADA) INCORPORATED (CA) | 2005-01-13 | — | — | US | disclosed |
| US-20040176608-A1 | Novel transition-metal complexes and use thereof in transition-metal catalyzed reactions | BAYER CHEMICALS AG (DE) | 2004-09-09 | — | — | US | disclosed |
| US-20030158173-A1 | Drugs for treating physiological disorder, respiratory disorders, inflammatory disease, skin disorder, and antidepressants, treating bipolar disorder, drug abuse, drug dependence, gastrointestinal disorder, atherosclerosis | SCHERING CORPORATION | 2003-08-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009804-A1 | Compounds and methods for the treatment or prevention of Flavivirus infections | ZC3HAV1, ZYX, ZFX | CRHR1 4488/4885MAPT 1641/4885LMNA 1242/4885 |
| US-20040176608-A1 | Novel transition-metal complexes and use thereof in transition-metal catalyzed reactions | AP1M1, SOD1, INTS9 | CRHR1 3947/4885MAPT 2516/4885LMNA 4057/4885 |
| US-20140336158-A1 | NK1 ANTAGONISTS | HRH4, CRHR2, HRH2 | CRHR1 4/4885MAPT 3065/4885LMNA 3549/4885 |
| US-20060115448-A1 | Amphiphilic polynorbornene derivatives and methods of using the same | PHOSPHO1, DDOST, NCL | CRHR1 4228/4885MAPT 4467/4885LMNA 621/4885 |
| US-20130023503-A1 | NK1 ANTAGONISTS | HRH4, CRHR2, HRH2 | CRHR1 4/4885MAPT 3065/4885LMNA 3549/4885 |
| US-20030158173-A1 | Drugs for treating physiological disorder, respiratory disorders, inflammatory disease, skin disorder, and antidepressants, treating bipolar disorder, drug abuse, drug dependence, gastrointestinal disorder, atherosclerosis | ADRA1D, HTR1D, NR3C1 | CRHR1 74/4885MAPT 1194/4885LMNA 2268/4885 |
| US-20090149444-A1 | Benzylamine analogues | HTR4, DRD4, SLC6A4 | CRHR1 150/4885MAPT 1050/4885LMNA 3778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.